GFF MDI for the improvement of lung function in COPD – A look at the PINNACLE-1 and PINNACLE-2 data and beyond

References

• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
   PubMed Web of Science ®Google Scholar
• Burney PG, Patel J, Newson R, et al. Global and regional trends in COPD mortality, 1990-2010. Eur Respir J. 2015;45:1239–1247.
   PubMed Web of Science ®Google Scholar
• Bhome AB. COPD in India: iceberg or volcano?. J Thorac Dis. 2012;4:298–309.
   PubMed Web of Science ®Google Scholar
• European Respiratory Society. European lung white book. 2016. [cited 2016 Dec 14]. Available from: http://www.erswhitebook.org/
   Google Scholar
• Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004;9:458–465.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64:863–868.
   PubMed Web of Science ®Google Scholar
• Nascimento OA, Camelier A, Rosa FW, et al. Chronic obstructive pulmonary disease is underdiagnosed and undertreated in Sao Paulo (Brazil): results of the PLATINO study. Braz J Med Biol Res. 2007;40:887–895.
   PubMed Web of Science ®Google Scholar
• Shahab L, Jarvis MJ, Britton J, et al. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax. 2006;61:1043–1047.
   PubMed Web of Science ®Google Scholar
• Landis SH, Muellerova H, Mannino DM, et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis. 2014;9:597–611.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 2017, 2017 [cited 2016 Nov 18]. Available from: http://www.goldcopd.org
   Google Scholar
• World Health Organization. Chronic obstructive pulmonary disease (COPD), 2016 [cited 2016 Dec 14]. Available from: http://www.who.int/mediacentre/factsheets/fs315/en/
   Google Scholar
• McCloskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med. 2001;164:1419–1424.
   PubMed Web of Science ®Google Scholar
• Thomsen M, Nordestgaard BG, Vestbo J, et al. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. Lancet Respir Med. 2013;1:543–550.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47:625–637.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–191.
   PubMed Web of Science ®Google Scholar
• Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;10:CD008989.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43:1599–1609.
   PubMed Web of Science ®Google Scholar
• Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109:1312–1319.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199–209.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:1068–1079.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257–267. .
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.
   PubMed Web of Science ®Google Scholar
• Yu AP, Guerin A, Ponce De Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14:486–496.
   PubMedGoogle Scholar
• Yu AP, Guérin A, De Leon DP, et al. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med. 2011;105:1861–1871.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939–943.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Corrigan CJ, Barnes PJ, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105:1099–1103.
   PubMed Web of Science ®Google Scholar
• Bonini M, Usmani OS. The importance of inhaler devices in the treatment of COPD. COPD Res Pract. 2015;1:9.
   Google Scholar
• Braido F, Lavorini F, Blasi F, et al. Switching treatments in COPD: implications for costs and treatment adherence. Int J Chron Obstruct Pulmon Dis. 2015;10:2601–2608.
   PubMed Web of Science ®Google Scholar
• Doyle S, Lloyd A, Williams A, et al. What happens to patients who have their asthma device switched without their consent?. Prim Care Respir J. 2010;19:131–139.
   PubMedGoogle Scholar
• Haidl P, Heindl S, Siemon K, et al. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med. 2016;118:65–75.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26:174–179.
   PubMed Web of Science ®Google Scholar
• Prime D, De Backer W, Hamilton M, et al. Effect of disease severity in asthma and chronic obstructive pulmonary disease on inhaler-specific inhalation profiles through the ELLIPTA dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2015;28:486–497.
   PubMed Web of Science ®Google Scholar
• Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS Pharmscitech. 2014;15:434–455.
   PubMed Web of Science ®Google Scholar
• Stein SW, Sheth P, Hodson PD, et al. Advances in metered dose inhaler technology: hardware development. AAPS Pharmscitech. 2014;15:326–338.
   PubMed Web of Science ®Google Scholar
• Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28:15015–15023.
   PubMed Web of Science ®Google Scholar
• Hatley RH, Parker J, Pritchard JN, et al. Variability in delivered dose from pressurized metered-dose inhaler formulations due to a delay between shake and fire. J Aerosol Med Pulm Drug Deliv. 2016;30:71–79.
   PubMed Web of Science ®Google Scholar
• Joshi V, Lechuga-Ballesteros D, Flynn B, et al. Development of mono, dual and triple combination pMDIs without co-formulation effect. Resp Drug Delivery Europe. 2011;2:383–386.
   Google Scholar
• Lechuga-Ballesteros D, Noga B, Vehring R, et al. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3:1703–1718.
   PubMed Web of Science ®Google Scholar
• Mack P, Doty A, Schroeder J, et al. Drug delivery from a novel LAMA/LABA Co-Suspension Technology of glycopyrrolate/formoterol fixed-dose combination MDI: evidence of consistency, robustness and patient-use reliability. 2016: A5839. [cited 2016 Dec 14]. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5839
   Google Scholar
• Novartis. Seebri Neohaler Prescribing Information, 2015 [cited 2016 Dec 14]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207923lbl.pdf
   Google Scholar
• Novartis. Seebri Breezhaler Summary of Product Characteristics, 2016[cited 2016 Dec 14]. Available from: https://www.medicines.org.uk/emc/medicine/27138
   Google Scholar
• Novartis. Foradil Aerolizer Prescribing Information, 2012 [cited 2016 Dec 14]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020831s028lbl.pdf
   Google Scholar
• Novartis. Foradil Summary of Product Characteristics, 2016 [cited 2016 Dec 14]. Available from: https://www.medicines.org.uk/emc/medicine/1286
   Google Scholar
• Brusasco V, Canonica GW, Dal NR, et al. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD. J Aerosol Med Pulm Drug Deliv. 2011;24:235–243.
   PubMed Web of Science ®Google Scholar
• Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005;99:1511–1520.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.
   PubMed Web of Science ®Google Scholar
• Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778–784.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40:1106–1114.
   PubMed Web of Science ®Google Scholar
• Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;10:CD010177.
   PubMed Web of Science ®Google Scholar
• Quinn D, Seale JP, Reisner C, et al. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD. Respir Med. 2014;108:1327–1335.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Di Marco F, et al. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49.
   PubMed Web of Science ®Google Scholar
• St Rose E, Strom S, Fischer T, et al. Pharmacokinetic (PK) bioequivalence and comparable efficacy/safety were demonstrated with Pearl Therapeutics’ formoterol fumarate MDI (FF MDI, PT005) compared to Foradil® Aerolizer® in a randomized, double-blind, placebo-controlled phase 2b study in patients with moderate to very severe chronic obstructive pulmonary disease. 2012: A2927. [cited 2016 Jun 17]. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2927
   Google Scholar
• Reisner C, Kerwin EM, Spangenthal S, et al. Pearl Therapeutics’ LAMA MDI (GP MDI, PT001) provides a significant benefit in forced expiratory volume in 1 second (FEV1) in doses ranging from 36 µg to 4.6 µg compared to Atrovent HFA, and placebo in a randomized, double-blind, placebo-controlled phase IIb study In patients with COPD. 2013: A4267. [cited 2016 Jun 21]. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A4267
   Google Scholar
• Reisner C, Orevillo C, Fernandez C, et al. Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) 18/9.6 μg for phase III development. 2013 [cited 2016 Jun 1]. Available from: http://erj.ersjournals.com/content/42/Suppl_57/P4153
   Google Scholar
• Orevillo C, Gotfried M, Denenberg MB, et al. Combination glycopyrronium and formoterol fumarate inhalation aerosol (PT003) at a dose of 14.4/9.6 µg provides superior improvement in inspiratory capacity compared to tiotropium dry powder inhaler (DPI) in subjects with moderate to severe COPD. 2014: A3759. [cited 2016 June 14]. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A3759
   Google Scholar
• Reisner C, Fernandez C, St Rose E, et al. Characterization of the dose response of Pearl Therapeutics’ LAMA MDI (GP MDI, PT001) from 36 micrograms to 600 nanograms BID; results from an integrated analysis of phase IIb studies in patients with COPD. 2013: A4274. [cited 2016 Jun 15]. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A4274
   Google Scholar
• Tashkin DP, Martinez FJ, Rodriguez-Roisin R, et al. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respir Med. 2016;120:16–24.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Kerwin EM, Spangenthal S, et al. Dose-response to inhaled glycopyrrolate delivered with a novel Co Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Respir Res. 2016;17:109.
   PubMed Web of Science ®Google Scholar
• Sethi S, Fogarty C, Hanania NA, et al. Efficacy of formoterol fumarate delivered by metered dose inhaler using Co-Suspension™ Delivery Technology versus Foradil® Aerolizer® in moderate-to-severe COPD: a randomized, dose-ranging study. Chronic Obstr Pulm Dis (Miami). 2017;4:21–33.
   Google Scholar
• Rennard S, Fogarty C, Reisner C, et al. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:118.
   PubMed Web of Science ®Google Scholar
• Beier J, Kirsten AM, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. Copd. 2013;10:511–522.
   PubMedGoogle Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using Co-Suspension Delivery Technology in patients with COPD. Chest. 2017;151:340–357.
   Google Scholar
• AstraZeneca Pharmaceuticals LP Bevespi Aerosphere Prescribing Information, 2016 [cited 2016 Nov 11]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208294s000lbl.pdf
   Google Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472–486.
   PubMed Web of Science ®Google Scholar
• Dahl R, Jadayel D, Alagappan VK, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis. 2013;8:501–508.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538–1546.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484–1494.
   PubMed Web of Science ®Google Scholar
• Karloh M, Fleig Mayer A, Maurici R, et al. The COPD Assessment Test: what do we know so far?: A systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest. 2016;149:413–425.
   PubMed Web of Science ®Google Scholar
• Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med. 2011;11:42.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Fernandez-Villar A, Calero-Acuna C, et al. Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:975–984.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831–838.
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327.
   PubMed Web of Science ®Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. Copd. 2005;2:111–124.
   PubMedGoogle Scholar
• Hanania NA, Tashkin DP, Kerwin EM, et al. Long term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;26:105–115.
   Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by COPD patients. Am J Respir Crit Care Med. 2016; Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Braido F, Chrystyn H, Baiardini I, et al. “Trying, but failing” − The role of inhaler technique and mode of delivery in respiratory medication adherence. J Allergy Clin Immunol Pract. 2016;4:823–832.
   PubMed Web of Science ®Google Scholar
• Cohen JS, Miles MC, Donohue JF, et al. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct Pulmon Dis. 2016;11:785–797.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108:584–592.
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123.
   PubMed Web of Science ®Google Scholar
• Price D, Small M, Milligan G, et al. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595–603.
   PubMed Web of Science ®Google Scholar
• Stephenson JJ, Cai Q, Mocarski M, et al. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:577–586.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59.
   PubMed Web of Science ®Google Scholar
• Sanguinetti CM. The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients. Multidiscip Respir Med. 2014;9:19.
   PubMedGoogle Scholar
• O’Donnell DE. Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance. Eur Resp Rev. 2006;15:37–41.
   Google Scholar
• Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109:870–881.
   PubMed Web of Science ®Google Scholar
• Singh D, Maleki-Yazdi MR, Tombs L, et al. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424.
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–1036.
   PubMed Web of Science ®Google Scholar
• Wang CY, Lai CC, Yang WC, et al. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study. Int J Chron Obstruct Pulmon Dis. 2016;11:2775–2783.
   PubMed Web of Science ®Google Scholar
• Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163:461–464.
   PubMed Web of Science ®Google Scholar